AI Cancer Detection Startup Nucleai Raises $5 Million

Tel Aviv-based Nucleai Ltd. announced on Monday it completed a $5 million Seed Round led by Vertex Ventures Israel and Grove Ventures Capital (GP) Ltd. Nucleai develops software that uses computer vision and machine learning algorithms to detect signs of cancer and gastrointestinal diseases. For daily updates, subscribe to our newsletter by clicking here. Today, most disease diagnoses are performed by pathologists by examining tissues and cells taken from the body during a biopsy to detect abnormalities. Nucleai's technology is designed to improve the efficiency of pathologists, reduce errors, and shorten patients' wait time for a diagnosis, the company said in a statement.